The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia.

MLA

Tonstad, S., et al. “The Effect of the Gastrointestinal Lipase Inhibitor, Orlistat, on Serum Lipids and Lipoproteins in Patients with Primary Hyperlipidaemia.” European Journal of Clinical Pharmacology, vol. 46, no. 5, 1994, pp. 405–10. EBSCOhost, https://doi.org/10.1007/BF00191901.

APA

Tonstad, S., Pometta, D., Erkelens, D. W., Ose, L., Moccetti, T., Schouten, J. A., Golay, A., Reitsma, J., Del Bufalo, A., Pasotti, E., & et. al. (1994). The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. European Journal of Clinical Pharmacology, 46(5), 405–410. https://doi.org/10.1007/BF00191901

Chicago

Tonstad, S, D Pometta, D W Erkelens, L Ose, T Moccetti, J A Schouten, A Golay, et al. 1994. “The Effect of the Gastrointestinal Lipase Inhibitor, Orlistat, on Serum Lipids and Lipoproteins in Patients with Primary Hyperlipidaemia.” European Journal of Clinical Pharmacology 46 (5): 405–10. doi:10.1007/BF00191901.